Transgene Biotek Ltd
BSE:526139

Watchlist Manager
Transgene Biotek Ltd Logo
Transgene Biotek Ltd
BSE:526139
Watchlist
Price: 6.94 INR -6.34% Market Closed
Market Cap: 525.8m INR
Have any thoughts about
Transgene Biotek Ltd?
Write Note

Transgene Biotek Ltd
Long-Term Debt

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Transgene Biotek Ltd
Long-Term Debt Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Long-Term Debt CAGR 3Y CAGR 5Y CAGR 10Y
Transgene Biotek Ltd
BSE:526139
Long-Term Debt
â‚ą49.6m
CAGR 3-Years
2%
CAGR 5-Years
4%
CAGR 10-Years
N/A
Bharat Immunologicals and Biologicals Corporation Ltd
BSE:524663
Long-Term Debt
â‚ą35m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Z
Zenotech Laboratories Ltd
BSE:532039
Long-Term Debt
â‚ą0
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Hester Biosciences Ltd
NSE:HESTERBIO
Long-Term Debt
â‚ą1.6B
CAGR 3-Years
22%
CAGR 5-Years
23%
CAGR 10-Years
N/A
Biocon Ltd
NSE:BIOCON
Long-Term Debt
â‚ą134.2B
CAGR 3-Years
62%
CAGR 5-Years
50%
CAGR 10-Years
33%
Panacea Biotec Ltd
NSE:PANACEABIO
Long-Term Debt
â‚ą215.7m
CAGR 3-Years
-69%
CAGR 5-Years
-49%
CAGR 10-Years
N/A
No Stocks Found

Transgene Biotek Ltd
Glance View

Market Cap
525.8m INR
Industry
Biotechnology

Transgene Biotek Ltd. is a biotechnology company, which manufactures and sells diagnostic kits. The company is headquartered in Medak, Telangana. The firm is engaged in a single business segment of Bulk Drugs. Its portfolio of products includes oncology, auto-immunity, drug delivery and biogenerics. The firm offers TrabiAAV, which is a platform for the delivery of micro ribonucleic acids (miRNAs), short hairpin RNA (ShRNAs), immunogens developing clinical significance in gene therapy. The company also offers monoclonal antibody therapy is the use of monoclonal antibodies to specifically bind to target cells. Its TrabiORAL focused on delivering proteins and peptides orally for a variety of human diseases. Its TBL-0404, is used for the treatment of metastatic liver cancer. Its TBL-1203, is used to strengthen cell-mediated immunity and complete elimination of the human immunodeficiency virus (HIV), without any need for retroviral drug therapy. Its Tacrolimus is a drug that suppresses the immune system and is mainly used to prevent rejection of transplanted organs.

TRABI Intrinsic Value
0.29 INR
Overvaluation 96%
Intrinsic Value
Price

See Also

What is Transgene Biotek Ltd's Long-Term Debt?
Long-Term Debt
49.6m INR

Based on the financial report for Sep 30, 2024, Transgene Biotek Ltd's Long-Term Debt amounts to 49.6m INR.

What is Transgene Biotek Ltd's Long-Term Debt growth rate?
Long-Term Debt CAGR 5Y
4%

Over the last year, the Long-Term Debt growth was -1%. The average annual Long-Term Debt growth rates for Transgene Biotek Ltd have been 2% over the past three years , 4% over the past five years .

Back to Top